Paper Details

  1. Home
  2. Paper Details

A double-blind comparison of loxapine succinate and trifluoperazine in newly admitted schizophrenic patients.

Author: CuculicZ, SimpsonG M

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.

Overview

Loxapine succinate was as effective as trifluoperazine in treating newly admitted schizophrenic patients. Both drugs significantly improved symptoms and signs, as measured by the BPRS and CGI. The two groups had similar discharge and termination rates and similar rates and severity of side effects.
Paper Details　
Original Abstract of the Article :
A study was conducted evaluating the efficacy of loxapine succinate in newly admitted schizophrenic patients through a four-week double-blind comparison with trifluoperazine. Twenty-four patients received between 40 and 80 mg loxapine succinate daily and 19 patients received between 20 and 50 mg tri...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/j.1552-4604.1976.tb01492.x

データ提供：米国国立医学図書館（NLM）

Loxapine Succinate: A New Oasis in the Treatment of Schizophrenia

Schizophrenia, a complex mental illness, has long been a challenge for healthcare providers. This study investigated the effectiveness of loxapine succinate, a new drug, in treating newly admitted schizophrenic patients. Imagine schizophrenia as a bewildering desert, full of distortions and difficulties, and loxapine succinate as a refreshing oasis, offering potential relief.

The researchers conducted a double-blind comparison study, evaluating the efficacy of loxapine succinate against trifluoperazine, a standard treatment. They found that both drugs led to significant improvements in symptoms, with no significant differences in discharge rates or side effects. This research suggests that loxapine succinate is a viable treatment option for schizophrenia.

A New Path: Hope for Schizophrenia Treatment

This study offers a glimmer of hope for individuals struggling with schizophrenia. The findings suggest that loxapine succinate, as a new drug, can effectively manage symptoms and provide relief. This discovery opens the door for new approaches to treatment, potentially leading to better outcomes for those living with this complex mental illness.

Navigating the Desert: Seeking Relief and Recovery

Schizophrenia presents a challenging journey through a desert of distorted perceptions and realities. This study, however, offers a potential oasis, suggesting that loxapine succinate can provide relief and support for those navigating this difficult terrain. The researchers' findings encourage the continued exploration of new treatments, seeking to illuminate the path towards recovery for those affected by this illness.

Dr. Camel's Conclusion

This study highlights the ongoing quest to find effective treatments for schizophrenia. Loxapine succinate emerges as a promising new oasis, offering hope and relief to those navigating the desert of this challenging illness. The researchers' work reminds us that progress is possible, and continued exploration will lead to better treatments and brighter futures for those impacted by schizophrenia.

Date :
  1. Date Completed 1976-04-02
  2. Date Revised 2019-08-23
Further Info :

Pubmed ID

1107360

DOI: Digital Object Identifier

10.1002/j.1552-4604.1976.tb01492.x

Related Literature

Article Analysis
・Side Effects of loxapine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.